Phase I, Sequential Dose Escalation Clinical Study to Investigate the Safety, Tolerability and Pharmacokinetics of in Patients With Advanced Solid Tumor
Investigate the safety and tolerability of multiple DCBCI0901 infusions in patients with advanced solid tumor
Pharmacokinetic parameters will be calculated for DCBCI0901, if data permit.
Anti tumor activity: The efficacy endpoint will be the overall response rate (ORR) defined as the proportion of patients who continuously receive treatment after Cycle 1 with a best overall response of complete response (CR) or partial response (PR).
100 项与 DCBCI-0901 相关的临床结果
100 项与 DCBCI-0901 相关的转化医学
100 项与 DCBCI-0901 相关的专利(医药)
100 项与 DCBCI-0901 相关的药物交易